Search

Additional file 4: Supplementary Table 4. Sensitivity analysis 1: Characteristics detailed by disease in patients who discontinued therapy on achieving remission (data at 6 months after discontinuation). Footnote to supplementary table 3: Disc.: Discontinuation; Rem: remission; b-DMARD: biologic-disease modifying antirheumatic drug; m: Months Rem: remission; RA: rheumatoid arthritis; AS: ankylosing spondylitis; PsA: psoriatic arthritis; csDMARD: conventional synthetic DMARD; MTX: methotrexate, LFN: leflunomide; SSZ: sulfasalazine; i: inhibitor; Abt: abatacept; RF: rheumatoid factor; ACPA: anti–citrullinated peptide antibody. *Moderate-high disease activity was defined as DAS28 ≥3.2 or BASDAI ≥4, depending on the disease.

Additional file 6: Supplementary Table 6. 2nd Sensitivity analysis. Regression analysis by disease comparing patients who discontinued therapy according to clinical remission vs patients who continue. Footnote to Table 3: OR: odds ratio. 95% CI: 95% confidence interval. TNF-i: tumor necrosis factor alfa inhibitor. RA: rheumatoid arthritis; AS: ankylosing spondylitis; PsA: psoriatic arthritis: RF rheumatoid factor; ACPA: anti–citrullinated peptide antibody. Note: There were no ex-smokers for AS.

Additional file 3: Supplementary Table 3. Sensitivity analysis 1: Clinical characteristics of patients who discontinued on achieving remission (data at 6 months after discontinuation). Footnote to supplementary table 2: P Rem: probability of remission/no remission at 6 months; Rem: remission; i: inhibitor; RA: rheumatoid arthritis; AS: ankylosing spondylitis; PsA: psoriatic arthritis; bDMARD: biologic disease-modifying antirheumatic drug; csDMARD: conventional synthetic DMARD; tsDMARD: targeted synthetic DMARD; MTX: methotrexate, LFN: leflunomide; SSZ: sulfasalazine; i: inhibitor; RF: rheumatoid factor; ACPA: anti–citrullinated peptide antibody. *Moderate-high disease activity was defined as DAS28 ≥3.2 or BASDAI ≥4, depending on the disease.

Additional file 5: Supplementary Table 5. 2nd sensitivity analysis .Regression models for all the diseases together comparing patients who discontinued therapy according to clinical remission vs patients who continue. Footnote to table 2: OR: odds ratio. 95% CI: 95% confidence interval. TNF-i: tumor necrosis factor alfa inhibitor. RA: rheumatoid arthritis; AS: ankylosing spondylitis; PsA: psoriatic arthritis. csDMARD: conventional synthetic DMARD. * High activity: DAS28 ≥3.2 or BASDAI ≥4.

Additional file 1: Supplementary Table 1. Baseline characteristics of patients by disease. Footnote to supplementary table 1. Data are shown as mean (standard deviation), except for categorical variables, where they are expressed as n (%). RA: rheumatoid arthritis; AS: ankylosing spondylitis; PsA: psoriatic arthritis; bDMARD: biologic disease-modifying antirheumatic drug; csDMARD: conventional synthetic DMARD; tsDMARD: targeted synthetic DMARD; MTX: methotrexate, LFN: leflunomide; SSZ: sulfasalazine; i: inhibitor; RF: rheumatoid factor; ACPA: anti–citrullinated peptide antibody. *Moderate-high disease activity was defined as DAS28 ≥3.2 or BASDAI ≥4, depending on the disease.

Additional file 2: Supplementary Table 2. (2nd Sensitivity analysis). Demographic and clinical characteristics of patients with inflammatory arthritis who discontinued therapy according to clinical remission vs patients who continue. Footnote to table 1. Data are shown as mean (SD), except for categorical variables, which are shown as total number (percentage); Disc: Discontinuation; Rem: Remission; MTX: methotrexate, LFN: leflunomide; SSZ: sulfasalazine; i: inhibitor; RF: rheumatoid factor; ACPA: anti–citrullinated peptide antibody. *Moderate-high disease activity was defined as DAS28 ≥3.2 or BASDAI ≥4, depending on the disease.